Bristol-Myers Squibb Appoints Saurabh Saha, M.D., Ph.D., as Senior Vice President, Global Head of Translational Medicine
October 09 2017 - 6:59AM
Business Wire
Bristol-Myers Squibb Company (NYSE: BMY) announced that it has
appointed scientific and business thought-leader, Saurabh Saha,
M.D., Ph.D., as senior vice president and global head of
translational medicine in the company’s R&D organization,
effective today.
“Enhancing our translational medicine capability is critical to
achieving our mission, and we are excited to add Dr. Saha’s broad
leadership experience and deep scientific expertise to our team,”
said Tom Lynch, M.D., executive vice president and chief scientific
officer of Bristol-Myers Squibb. “Dr. Saha will lead translational
research across our therapeutic areas of focus to ensure we have
the best understanding of disease and asset-specific biology so we
can deliver the right drug to the right patient at the right
time.”
Dr. Saha said, “Throughout my career, I have had a passion for
developing translational research strategies across disease areas,
including oncology and immunology. I look forward to working with
Tom and the rest of the R&D organization to advance
Bristol-Myers Squibb’s industry-leading pipeline in a way that
pushes the boundaries of science and enables us to rapidly deliver
innovative medicines to patients with even greater precision.”
Dr. Saha will initially be based at the company’s Waltham, Mass
research site until its new state-of-the-art research site in
Cambridge, Mass opens in the fourth quarter of 2018.
About Dr. Saurabh Saha
Dr. Saha’s extensive research experience includes leading
groundbreaking translational research and implementing innovative
drug discovery strategies that have resulted in the discovery and
development of two first-in-class cancer therapies and the
pioneering of new approaches for unmet medical needs across
therapeutic areas and clinical modalities.
Prior to joining Bristol-Myers Squibb, Dr. Saha was a venture
partner at Atlas Venture where he held leadership positions with
many of its portfolio biotech companies, including as chief medical
officer of Synlogic, and as chief executive officer of Delinia
until its sale to Celgene in early 2017. In 2008, Dr. Saha
established the translational research and development organization
BioMed Valley Discoveries where he served as chief scientific
officer and later president, and was responsible for leading the
development and demonstrating human effectiveness of novel cancer
drugs for refractory and resistant disease, including an ERK
inhibitor and a bacteriolytic immunotherapy. Earlier in his career,
Dr. Saha was a consultant in the pharmaceutical practice at
McKinsey and Company and subsequently appointed director and head
of the New Indications Discovery Unit at Novartis. Dr. Saha is on
the editorial boards of numerous prestigious medical journals and
is an associate member and global clinical scholar at Harvard
Medical School.
Dr. Saha holds an M.D. and Ph.D. in cancer genetics from The
Johns Hopkins School of Medicine, where he completed his graduate
studies in Bert Vogelstein’s lab. He is an alumnus of Harvard
Business School and Oxford University, studying general management
and biophysics respectively. Dr. Saha completed his undergraduate
studies in biochemistry from the California Institute of Technology
(Caltech).
About Bristol-Myers
Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter, YouTube and Facebook.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171009005115/en/
Bristol-Myers SquibbMedia:Sarah Koenig,
609-252-4145Sarah.koenig@bms.comorInvestors:Tim Power,
609-252-7509Timothy.power@bms.comorBill Szablewski,
609-252-5894william.szablewski@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024